The world's first hexavalent rotavirus vaccine has been approved for market launch

Wallstreetcn
2025.08.22 10:30

Recently, the oral six-valent reassortant rotavirus live attenuated vaccine (Vero cells) developed by China National Pharmaceutical Group Wuhan Institute of Biological Products (brand name: WuShengEr LunBao®) has officially been approved for marketing by the National Medical Products Administration. This product is the world's first and highest-priced rotavirus vaccine, classified as a Category 1 new drug for preventive biological products in China, primarily used for the prevention of acute gastroenteritis in infants and young children caused by rotavirus

Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.